ADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial.
June 4, 2026 07:01 AM EDT
R&DPharmaFDA+
ADC Therapeutics' confirmatory data for Zynlonta muddied by death rates
Reynald Castaneda
Deputy Editor
ADC Therapeutics' shares plummet after patient deaths in trial of Zynlonta
Why Is ADC Therapeutics Stock Falling Thursday? - ADC Therapeutics (NYSE:ADCT)
EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
ASCO: Sac-TMT’s massive phase 3 program has a jarring gap. Does Merck plan to close it?
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker
ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC - Pharmaceutical Technology
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
Breakthrough offers new hope for patients with relapsed blood cancer
Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised questions…
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
AbbVie’s ultra-rare blood cancer ADC secured FDA clearance while AstraZeneca’s oral SERD for breast cancer remains in regulatory…
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in…
ASCO: Incyte details Monjuvi’s frontline data in lymphoma; Lilly appears in two plenaries
